Curaleaf Escalates Hostile Bid: Reveals Aurora Sold Shares at US$3.09–$3.57, Far Below Its Own Rejection Price
CURLF sits 86% above its 52-week low of $5.4.
Summary
Curaleaf responded to Aurora's Directors' Circular with new data showing Aurora's board sold shares at US$3.09–$3.57 via ATM programs — far below the US$4.00 offer it now rejects — while highlighting Aurora's US$398 million in dilution and negative cash flow.
Key Events · M&A and Partnerships · CURLF
-
Aurora Board Sold Below Offer Price
Aurora's board approved ATM sales at average prices of US$3.57 in fiscal 2026 and US$3.09 in the June quarter — materially below the US$4.00 per share Curaleaf offer Aurora now rejects.
-
Aurora Dilution Quantified
Aurora raised approximately US$398 million through dilutive equity issuances since September 2020, diluting shareholders by approximately 31%, with additional ATM capacity still available.
-
Aurora Cash Burn Exposed
Aurora's operating cash flow was negative C$4.4 million in the June quarter, while Curaleaf generated US$145 million of operating cash flow over the LTM period ended June 30, 2026.
-
Premium Defense Reinforced
Curaleaf's US$5.00 cap represents an 82% premium to Aurora's 30-day VWAP on the unaffected date of August 10, 2026, and a 197% premium on an ex-cash basis.
Analysis · CURLF · Life Sciences
Curaleaf's latest rebuttal to Aurora's Directors' Circular introduces new, specific financial ammunition: Aurora's own board approved ATM sales at US$3.57 and US$3.09 per share in recent quarters — prices materially below the US$4.00 offer Aurora now calls inadequate. The filing also quantifies Aurora's cumulative dilution (US$398 million raised since September 2020, ~31% dilution) and negative operating cash flow (C$4.4 million in the June quarter). These figures directly undercut Aurora's defense and strengthen Curaleaf's case that its 45% premium offer is the best path for Aurora shareholders. The hostile bid remains the central thesis-altering event for both companies, and this filing adds concrete data points that could sway institutional and retail shareholders ahead of any vote or tender deadline.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $10.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.